admin
Wall Street woke up to a wake-up call for American innovation Wednesday as Moderna’s stock exploded after the company and partner Merck announced positive results from a late-stage melanoma trial. Shares more than doubled when trading opened, a market thunderclap that proved once again that when private companies deliver real results, investors respond immediately.
The clinical news was precise and hard to spin: the individualized mRNA vaccine, known as intismeran, given with Merck’s KEYTRUDA, met the trial’s primary goal of improving recurrence-free survival and also hit a key secondary endpoint of reducing distant metastases in patients with completely resected high-risk melanoma. This was not a lab press conference — it was a Phase 3 readout in an over-1,100 patient study, the kind of trial that changes standards of care if regulators agree.
Make no mistake: this is a vindication of American biotech grit and the promise of mRNA beyond pandemic-era vaccines. Moderna and Merck have been working through multiple trials and follow-ups for years, and this result is a milestone for personalized neoantigen approaches that tailor therapy to a patient’s tumor mutations. The companies already signaled their belief in moving the program forward across tumor types, showing the private sector’s ability to push medical frontiers where big government labs and bureaucracies move too slowly.
Conservatives should celebrate what this moment represents: risk-takers investing capital, scientists and clinicians delivering outcomes, and patients getting new hope because markets rewarded bold work. Too often the left’s answer to high-stakes innovation is price controls, red tape and punishment for success, which would have strangled this kind of high-cost, high-skill endeavor before it ever matured. If Washington wants more cures, it should stop treating winners like villains and let private enterprise do what it does best — innovate and scale.
Investors will debate the degree to which this readout justifies the frenzy — and they should, because stock markets are loud and volatile after breakthrough headlines. But the bigger point is sober: a company that was written off by many after COVID-era swings has now delivered a potentially practice-changing cancer result, proving that entrepreneurial America can pivot, persevere and produce life-saving medicines.
For hardworking Americans watching from Main Street, the takeaway is simple and proud: when our biotech sector is allowed to operate, protected by the rule of law and fuelled by private capital, it builds breakthroughs that save lives and create wealth. Lawmakers ought to celebrate, not demonize, those who bring real cures to patients — and ensure regulations encourage more of this, not less.
